Last Updated: 14 Sep 2024
Executive Summary
Quest Diagnostics Incorporated (DGX) is a leading provider of clinical laboratory services in the United States and internationally. With a market capitalization of $17.19 billion, the company has a strong financial position and a track record of consistent growth. The stock is currently trading at $154.38, close to its 52-week high of $159.36. Analysts are generally bullish on the stock, with a consensus target price of $155.05.
Company Overview
Quest Diagnostics is a Fortune 500 company that operates in the United States, Puerto Rico, Mexico, and Brazil. The company provides a wide range of laboratory testing services, including routine blood tests, genetic testing, and cancer screening. Quest Diagnostics also has a network of patient service centers and outreach programs that make it easy for patients to access its services.
Fundamental Analysis
Quest Diagnostics has a strong financial profile. The company has a trailing price-to-earnings (PE) ratio of 20.83, which is below the industry average. The company also has a strong balance sheet, with $1.79 billion in EBITDA and $5.96 billion in book value.
The company's revenue and earnings have grown steadily in recent years. In 2023, Quest Diagnostics reported revenue of $9.35 billion and diluted EPS of $7.41. The company's revenue and earnings are expected to continue to grow in the coming years.
Technical Analysis
The technical analysis of Quest Diagnostics stock is mixed. The stock is currently trading above its 50-day and 200-day moving averages, which is a bullish sign. However, the stock is also nearing its 52-week high, which could be a sign that it is overbought.
Short Term Outlook
The short-term outlook for Quest Diagnostics stock is positive. The stock is trading near its 52-week high and analysts are generally bullish on the stock. However, the stock could be due for a pullback in the short term.
Long Term Outlook
The long-term outlook for Quest Diagnostics stock is positive. The company has a strong financial profile and a track record of consistent growth. The company's revenue and earnings are expected to continue to grow in the coming years.
Analyst Recommendations
Analysts are generally bullish on Quest Diagnostics stock. The consensus target price for the stock is $155.05, which is above the current price of $154.38. Five analysts have a Strong Buy rating on the stock, three analysts have a Buy rating, and ten analysts have a Hold rating.
